Dr. Jack Donovan Lemon, MD

Dr. Lemon practices at UCLA Medical Center in Los Angeles, California.

Dr. Lemon's NPI, 1003378019, was assigned on April 1, 2019. Dr. Lemon graduated from Lewis Katz School of Medicine in 2019. Dr. Lemon's California license number on file is A187679.

Dr. Lemon's primary practice is UCLA Medical Center, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 206-4083.

Dr. Lemon's primary practice is UCLA Medical Center in Los Angeles, California. Dr. Lemon is also affiliated with MedStar Georgetown University Hospital. The medical group on file is The Permanente Medical Group, Inc. Dmand AI also links Dr. Lemon to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lemon practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Lemon's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Lemon is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Lemon's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists age-related macular degeneration, dry eye and vitreous eye degeneration among the conditions Dr. Lemon treats.

CMS data shows 69 Medicare services from Dr. Lemon across 2 procedure codes in 2024, for 81 Medicare patients. Medicare paid $5,082 for them.

CMS counts 81 Medicare patients who saw Dr. Lemon in 2024. The largest group is 65 to 74, with 31 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 23% are also on Medicaid. Their average risk score is 1.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lemon's median patient age at 73, with 60% women.

In 2024, Dr. Lemon wrote 281 Medicare Part D claims for 148 patients. 73% of them were for generic drugs. CMS names the drug for 154 of them, across 5 drugs with 11 or more claims each, at $4,907 in total drug cost. In 2023, CMS named 156 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Lemon for performance year 2024, reported as part of a group. Dr. Lemon accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Lemon, published from 2011 to 2025. Dr. Lemon's most frequent co-authors are Murtaza Khuzema Adam, MD, David Sarraf, MD and Edmund Tsui, MD.

Dmand AI links Dr. Lemon to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 10 general payments to Dr. Lemon from 8 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 88% of the total. Astellas Pharma US Inc paid the most, $250.

Dr. Lemon graduated from Lewis Katz School of Medicine in 2019.

Dr. Lemon is in network with 5 carriers, including Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.